ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
AREXVY, Pulver und Suspension zur Herstellung einer Injektionssuspension - 10
69310003 GlaxoSmithKline AG
AREXVY, Pulver und Suspension zur Herstellung einer Injektionssuspension02.05.2024
  02.05.2024
(J07BX05) 
WHO-DDD01.05.2029
10
08.08. 
B  
No 
IP 
   
k.A. 
  
7680693100039Impfstoffe
  
Composition
I): proteinum prae-fusionatum F viri sincitialis respiratorii 120 µg, trehalosum dihydricum, polysorbatum 80, kalii dihydrogenophosphas, dikalii phosphas anhydricus, pro vitro. II): Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. I) et II) corresp.: proteinum prae-fusionatum F viri sincitialis respiratorii 120 µg, trehalosum dihydricum, polysorbatum 80, kalii dihydrogenophosphas, dikalii phosphas anhydricus, Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, natrii chloridum, dinatrii phosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.78 mg, kalium 0.35 mg.
Packungsbestandteile
 
Source
Data was imported : 09.01.2026 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2026 ©ywesee GmbH
Settings | Help | Login | Contact | Home